Navigation Links
Mylan to Host Investor Day on Feb. 21, 2012, in New York City
Date:1/24/2012

NEW YORK, Jan. 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) will host an Investor Day on Feb. 21, in New York City.   Robert J. Coury, Mylan's executive chairman; Heather Bresch, chief executive officer; Rajiv Malik, president; Hal Korman, chief operating officer; John Sheehan, chief financial officer; and John Thievon, president of Dey Pharma,  will present the company's financial guidance for 2012 and an overview of the company's strategic vision and growth strategy for 2013 and beyond.  They will be joined by Tony Mauro, president of North America, and Didier Barret, president of Mylan's Europe, Middle East and Africa operations, for a question and answer session.

The presentations will be broadcast live via webcast beginning at 1 p.m. ET.  The meeting is expected to conclude by 5 p.m. ET. 

The company will issue its fourth quarter and full-year 2011 earnings results before the market opens on Feb. 21.

To access the live webcast and view the accompanying slide presentations, visit the Investor Relations section of Mylan's website, at http://investor.mylan.com, at least 15 minutes before the presentation is scheduled to begin; click on the webcast icon to register and download or install any necessary software.  If you are unable to view the live webcast, a replay will be available for 30 days on Mylan's website after the event's conclusion.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
2. Mylan Launches First Generic Version of Teveten® Tablets
3. Mylan Receives Approval for First-to-File Generic Keppra XR® Extended-Release Tablets
4. Mylan Receives WHO Approval for Innovative Second-Line-in-a-Box HIV/AIDS Treatment
5. Mylan Launches Generic Version of Toprol-XL® Tablets
6. Mylan Names John Thievon President of Dey Pharma
7. Mylan Launches Generic Version of Cyklokapron® Injection
8. Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS
9. Mylan Launches Generic Version of Caduet® Tablets
10. Mylan Confirms First-to-File Patent Challenge Relating to Generess™ Fe
11. Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 Companion animal ... in pets such as canine, avian and feline. ... types such as Attenuated Live Vaccines, Conjugate Vaccines, ... and Recombinant Vaccines. Attenuated live vaccines are derived ... which have been weakend under laboratory conditions. Conjugate ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group leased ... is developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company ... life-threatening diseases that have been underserved by scientific ... therapies for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... , April 18, 2017 Viverae ® , ... announce the integration of IBM ® Watson Campaign ... deliver targeted communications for a personalized experience. Through digital ... on their health in real time. The enhanced experience ... most to members, wherever they are in their journey ...
Breaking Medicine Technology:
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges ... for how his administration could impact the employee benefits industry. James Slotnick, AVP, ... most likely to make it through Congress. His discussion will focus on the ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental ... with dental fear and require sedation to receive dental care. The doctors offer three ... procedures, from hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... in unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as ... premier society for this important science. , The Teratology Society ...
Breaking Medicine News(10 mins):